HomeCompareBMY vs PTC

BMY vs PTC: Dividend Comparison 2026

BMY yields 4.17% · PTC yields 1.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BMY wins by $98.8K in total portfolio value
10 years
BMY
BMY
● Live price
4.17%
Share price
$59.73
Annual div
$2.49
5Y div CAGR
37%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$120.5K
Annual income
$39,823.66
Full BMY calculator →
PTC
PTC
● Live price
1.43%
Share price
$139.66
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.7K
Annual income
$157.13
Full PTC calculator →

Portfolio growth — BMY vs PTC

📍 BMY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBMYPTC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BMY + PTC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BMY pays
PTC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BMY
Annual income on $10K today (after 15% tax)
$354.34/yr
After 10yr DRIP, annual income (after tax)
$33,850.11/yr
PTC
Annual income on $10K today (after 15% tax)
$121.72/yr
After 10yr DRIP, annual income (after tax)
$133.56/yr
At 15% tax rate, BMY beats the other by $33,716.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BMY + PTC for your $10,000?

BMY: 50%PTC: 50%
100% PTC50/50100% BMY
Portfolio after 10yr
$71.1K
Annual income
$19,990.40/yr
Blended yield
28.11%
📊

Analyst Conviction Gap

Where Wall Street is split right now

BMY
Analyst Ratings
19
Buy
20
Hold
2
Sell
Consensus: Hold
Price Target
$62.73
+5.0% upside vs current
Range: $40.00 — $75.00
Altman Z
2.3
Piotroski
8/9
PTC
Analyst Ratings
20
Buy
10
Hold
3
Sell
Consensus: Buy
Price Target
$204.83
+46.7% upside vs current
Range: $180.00 — $255.00
Altman Z
5.4
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BMY buys
0
PTC buys
0
No recent congressional trades found for BMY or PTC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBMYPTC
Forward yield4.17%1.43%
Annual dividend / share$2.49$2.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR37%0%
Portfolio after 10y$120.5K$21.7K
Annual income after 10y$39,823.66$157.13
Total dividends collected$91.0K$1.5K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusHoldBuy
Analyst price target$62.73$204.83

Year-by-year: BMY vs PTC ($10,000, DRIP)

YearBMY PortfolioBMY Income/yrPTC PortfolioPTC Income/yrGap
1← crossover$11,271$571.12$10,843$143.20+$428.00BMY
2$12,884$824.20$11,747$145.12+$1.1KBMY
3$14,993$1,206.32$12,717$146.94+$2.3KBMY
4$17,839$1,797.27$13,755$148.65+$4.1KBMY
5$21,826$2,738.11$14,869$150.28+$7.0KBMY
6$27,643$4,289.31$16,061$151.81+$11.6KBMY
7$36,534$6,955.64$17,339$153.26+$19.2KBMY
8$50,861$11,770.13$18,707$154.63+$32.2KBMY
9$75,402$20,980.23$20,172$155.92+$55.2KBMY
10$120,504$39,823.66$21,742$157.13+$98.8KBMY

BMY vs PTC: Complete Analysis 2026

BMYHealthcare

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Full BMY Calculator →

PTCStock

PTC Inc. operates as software and services company in the Americas, Europe, and the Asia Pacific. The company operates in two segments, Software Products and Professional Services. It offers ThingWorx platform, which offers a set of capabilities that enable enterprises to digitally transform every aspect of their business with innovative solutions that are simple to create, easy to implement, scalable to meet future needs, and designed to enable customers to accelerate time to value; and Vuforia, which enables the visualization of digital information in a physical context and the creation of AR. The company also provides Onshape, a software-as-a-service product development platform unites computer-aided design with data management, collaboration tools, and real-time analytics; Arena, a PLM solution enables product teams to collaborate virtually anytime and anywhere; Creo, a 3D CAD technology enables the digital design, testing, and modification of product models; and Windchill, a product lifecycle management software. In addition, it offers Integrity, an application lifecycle management solution; Servigistics, service parts management solution; and consulting, implementation, training, cloud, and license and support services. The company was formerly known as Parametric Technology Corporation and changed its name to PTC Inc. in January 2013. PTC Inc. was incorporated in 1985 and is headquartered in Boston, Massachusetts.

Full PTC Calculator →
📬

Get this BMY vs PTC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BMY vs SCHDBMY vs JEPIBMY vs OBMY vs KOBMY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.